> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Updates Covid Clinical Trial Guidance
- URL: https://www.fdaweb.com/fda-updates-covid-clinical-trial-guidance/
- Published: 2020-05-12T12:00:00.000Z
- Updated: 2026-09-14T16:14:39.000Z
- Author: David McFarland
- Tags: Drugs, Devices, #legacy-id-D5146765

FDA has added content to the question-and-answer appendix in its guidance on conducting medical product clinical trials during the Covid-19 public health emergency. An online [notice](http://s2027422842.t.en25.com/e/es?s=2027422842&e=331853&elqTrackId=376c7bc788024cd5a73d955f2e3dcbdc&elq=892c63c9748e40489f5742d8a9f9f54f&elqaid=12491&elqat=1&ref=fdaweb.com) says the [guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-public-health-emergency?utm%5Fcampaign=SBIA%3A%20COVID%20CT%20GUIDANCE%20UPDATE&utm%5Fmedium=email&utm%5Fsource=Eloqua) includes new content with considerations for using alternate laboratories or imaging centers, holding trial participant visits via video conference, and conducting required postmarketing clinical trials.

“FDA is aware that protocol modifications may be required, and that there may be unavoidable protocol deviations due to Covid-19,” the notice says. “Although the impact of Covid-19 on trials will vary depending on factors such as the nature of disease under study, the trial design, and in what region(s) the study is being conducted, FDA’s guidance outlines general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice, and minimizing risks to trial integrity. The appendix further explains those considerations by responding to related questions the agency has received.”